RxDoctor Payments Data

Michael Lattanzio, DO

Nephrology · Whitehall, PANPI 1588844849

Payments from drug & device makers

$3,558in general payments, 2019–2025

Across 50 payments — averaging $71.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Otsuka America Pharmaceutical, Inc.$268
  • AstraZeneca$198
  • Bayer$124
  • Novartis$105
  • GSK$103
  • plus $453 from 13 others

What the payments were for

  • Food & beverage$1,25235%
  • Education$2,30665%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,558 in reported general payments places this provider in the 75th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$329,176
Medicare patients
762
Services billed
2,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol108$108,477
KerendiaFinerenone64$85,133
JardianceEmpagliflozin56$54,879
VeltassaPatiromer Calcium Sorbitex24$35,065
LokelmaSodium Zirconium Cyclosilicate38$34,519
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid27$16,865
Eplerenone28$2,824
Potassium Citrate ErPotassium Citrate13$1,334
Calcium Acetate19$1,120
Sevelamer Carbonate11$1,052
Bumetanide18$1,050
Losartan Potassium110$1,004
Nifedipine ErNifedipine32$999
Nebivolol Hcl23$986
Spironolactone53$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$198$142,996146 claims
BayerKerendia$124$85,13364 claims
ANI Pharmaceuticals, Inc.Valsartan$43$30715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Whitehall

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →